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See Editorial, pages 446–447Background & Aim: Primary sclerosing cholangitis (PSC) repre- p = 0.003, and p\0.0001 when compared to placebo), respec-
sents a devastating bile duct disease, currently lacking effective tively, while a +1.2% increase was observed in the placebo group.
medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side
chain-shortened C23 homologue of UDCA and has shown potent
anti-cholestatic, anti-inflammatory and anti-fibrotic properties
in a preclinical PSC mouse model. A randomized controlled trial,
including 38 centers from 12 European countries, evaluated the
safety and efficacy of three doses of oral norUDCA (500 mg/d,
1,000 mg/d or 1,500 mg/d) compared with placebo in patients
with PSC.
Methods: One hundred sixty-one PSC patients without concomi-
tant UDCA therapy and with elevated serum alkaline phos-
phatase (ALP) levels were randomized for a 12-week treatment
followed by a 4-week follow-up. The primary efficacy endpoint
was the mean relative change in ALP levels between baseline
and end of treatment visit.
Results: norUDCA reduced ALP levels by 12.3%, 17.3%, and
26.0% in the 500, 1,000, and 1,500 mg/d groups (p = 0.029,Journal of Hepatology 20
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points, such as ALT, AST, c-GT, or the rate of patients achieving
ALP levels\1.5 ULN. Serious adverse events occurred in seven
patients in the 500 mg/d, five patients in the 1,000 mg/d, two
patients in the 1500 mg/d group, and three in the placebo group.
There was no difference in reported pruritus between treatment
and placebo groups.
Conclusions: norUDCA significantly reduced ALP values dose-
dependently in all treatment arms. The safety profile of norUDCA
was excellent and comparable to placebo. Consequently, these
results justify a phase III trial of norUDCA in PSC patients.
Lay summary: Effective medical therapy for primary sclerosing
cholangitis (PSC) is urgently needed. In this phase II clinical study
in PSC patients, a side chain-shortened derivative of ursodeoxy-
cholic acid, norursodeoxycholic acid (norUDCA), significantly
reduced serum alkaline phosphatase levels in a dose-dependent
manner during a 12-week treatment. Importantly, norUDCA
showed a favorable safety profile, which was similar to placebo.
The use of norUDCA in PSC patients is promising and will be fur-
ther evaluated in a phase III clinical study.
ClinicalTrials.gov number: NCT01755507.
 2017 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).17 vol. 67 j 549–558
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Fig. 1. Trial design of the NUC-3 PSC study. Patients were screened for eligibility
and eligible patients were randomized in an equal ratio to either 500 mg/d,
1,000 mg/d, 1,500 mg/d norUDCA, or placebo. After randomization, control visits
were performed at week 0, 2, 4, 6, 8, 10, and 12. A follow-up visit was performed
4 weeks after end of study (week 16). UDCA, ursodeoxycholic acid; norUDCA,
norursodeoxycholic acid; wk or w, weeks; EOT, end of treatment.
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Introduction
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver
disease of unknown etiology characterized by a chronic inflam-
matory and fibro-obliterative destruction of extra-, and intrahep-
atic bile ducts.1 Currently there are no medical therapies with
proven benefits on PSC patients’ survival. The list of drugs that
have failed in PSC treatment is long, comprising of azathioprine,
cyclosporine, methotrexate, tacrolimus, penicillamine,
cholchicine, and infliximab.2 Consequently, liver transplantation
is the only treatment option for PSC patients with end-stage liver
disease. The use of ursodeoxycholic acid (UDCA) in the treatment
of PSC is highly controversial.3–5 Numerous studies showed
biochemical or histological improvements, but failed to demon-
strate significant differences in death rates, transplant-free sur-
vival, or development of cholangiocarcinoma.4–11 A randomized
controlled trial testing doses of UDCA ranging from 17 to
23 mg/kg/day showed a favorable biochemical trend but lacked
significant effects on hard clinical endpoints including
transplant-free survival, probably due to being underpowered.10
Testing even higher doses of UDCA (28–30 mg/kg/day) in PSC
patients revealed an overall improvement in serum liver tests
but were associated with a higher risk of death, a need for liver
transplantation, and increased rates of serious adverse events
(SAEs).11 Interestingly, a study on the effects of UDCA withdrawal
in PSC patients showed a significant deterioration of liver bio-
chemistry and symptoms within 3 months.12 Taken together,
effective medical therapy for PSC is still an unmet clinical need
and novel drugs are urgently needed.2
24-norursodeoxycholic acid (norUDCA) is a side chain-
shortened C23 homologue of UDCA and was previously shown
to be highly effective in preclinical mouse models of cholestatic
and fibrotic liver diseases.13–17 Comparing the therapeutic
effects of UDCA and norUDCA in Abcb4 knockout mice
(Abcb4/) as a model for sclerosing cholangitis and biliary
fibrosis revealed specific and superior anti-inflammatory, anti-
fibrotic, and anti-proliferative effects of norUDCA.14–16 The rela-
tive resistance of norUDCA to N-acyl-amidation with taurine or
glycine leads to cholehepatic shunting of norUDCA. This means
that unconjugated norUDCA, as a weak acid, can be reabsorbed
by cholangiocytes, returning to the sinusoids and hepatocytes
via the periductular capillary plexus, and is re-secreted into
bile.13,18–21 This process of cholehepatic shunting results in duc-
tal targeting and leads to profound stimulation of cholangiocel-
lular bicarbonate secretion and consequently induction of bile
acid-independent bile flow and flushing of bile ducts. In addi-
tion, biliary bicarbonate secretion may protect cholangiocytes
as a bicarbonate umbrella22 against their rather unfriendly envi-
ronment, where the apical surface membranes have to continu-
ously face millimolar concentrations of potentially toxic bile
acids.23 Moreover, norUDCA and its metabolites when secreted
into human bile are present in mostly monomeric rather than
micellar form, enhancing its osmotic effect thus making nor-
UDCA a highly potent choleretic drug.18 These favorable mech-
anisms of norUDCA and excellent tolerability in phase I
studies prompted us to initiate a multicenter placebo-
controlled phase II clinical trial (NUC-3/PSC) in PSC patients.
We aim to: (i) evaluate the efficacy of three doses of norUDCA
vs. placebo; (ii) identify efficacious norUDCA dose(s) for further
evaluation in a future phase III clinical trial; and (iii) to study
safety and tolerability of norUDCA.550 Journal of Hepatology 201Patients and methods
This study was designed as a European multicenter, double-blind, randomized,
placebo-controlled, comparative, and exploratory phase II dose finding trial with
four treatment groups. The overall study design is summarized in Fig. 1. Patients
were randomized to 500 mg/d, 1,000 mg/d or 1,500 mg/d norUDCA or placebo at
38 centers from 12 countries. Since the therapeutic efficacy of UDCA in PSC is
unclear it seemed justifiable to introduce a placebo arm. UDCA was therefore dis-
continued at least 8 weeks prior to baseline visit in 113 of 161 patients enrolled.
From 159 patients receiving the study medication 40 were documented as UDCA-
naïve, 58 classified as UDCA responders, and 55 as UDCA non-responders.
Response was defined as (partial) normalization of serum alkaline phosphatase
(ALP) at the investigator’s discretion (Table 2) and this study therefore lacks a
strict definition of UDCA response. Importantly, all UDCA exposed patients dis-
continued UDCA at least for 8 weeks prior to study inclusion. The biochemical
patterns following discontinuation of UDCA were in line with a previous report12
showing an increase in ALP (+27% in UDCA responder, +15% in UDCA non-
responders). A 12-week treatment phase was followed by a 4-week follow-up
period. The trial was performed between January 2013 and September 2015 fol-
lowing the principles of good clinical practice and in accordance with the ethical
principles of the Declaration of Helsinki, was registered with EudraCT (No. 2011-
002754-31), and approved by the independent local ethics committees responsi-
ble for the participating investigators.
All patients provided written informed consent. Male or female PSC patients
agedP18 and\80 years were included. PSC was verified by two of the three fol-
lowing criteria: (i) chronic cholestatic liver disease of at least 6 months duration;
(ii) retrograde, operative, percutaneous, or magnetic resonance cholangiography
demonstrating intrahepatic and/or extrahepatic biliary duct changes such as
beading or narrowing consistent with PSC within 1 year prior to baseline; or
(iii) liver biopsy available for review and compatible with the diagnosis of PSC.
ALP had to be elevated P1.5 upper limit of normal (ULN) at baseline. Both
PSC patients with or without irritable bowel disease (IBD) were included. Patients
without a definite diagnostic exclusion of IBD required a colonoscopy with seg-
mental biopsies prior to the baseline visit. Women of childbearing potential
had to apply a highly effective method of birth control.
Key exclusion criteria included history or presence of other concomitant liver
diseases such as secondary sclerosing cholangitis, primary biliary cholangitis,
cholangiocellular carcinoma, hepatitis B or C infection, Wilson’s disease,
haemochromatosis, autoimmune hepatitis, chronic alcoholic consumption (daily
consumption[30 g/d), or biopsy proven NASH. Child-Pugh score B/C liver cirrho-
sis and patients with history or presence of hepatic decompensation were
excluded. In addition, patients were excluded if receiving immunosuppressive
drugs such as chlorambucil, pentoxyfylline, penicillamine, pirfenidone, fibrates,
biologicals (e.g. anti-tumor necrosis factor-a therapy), or rifampicin treatment
3 months prior to baseline recording. Endoscopic treatment for bile duct stenosis
needed or planned within 5 months post randomization date and treatment for
dominant bile duct stenosis within 6 months prior to baseline visit were also
excluded. Moreover, patients with a total bilirubin[3.0 mg/dl ([50 lmol/L) at
screening or baseline or rise in total bilirubin of at least 50% within the last
6 months prior to baseline were excluded from this trial.7 vol. 67 j 549–558
222 screened
161 randomized
159 received study
medication
Intention to treat (ITT)
analysis
51 Pts. violated inclusion/exclusion criteria
5 Pts. withdrew their consent
2 Pts. used prohibited concomitant medication
1 Pt. had a 50% rise in bilirubin during screening
1 Pt. had a pretreatment SAE
1 Pt. due to general stop of randomization
2 withdrew prior to dosing
61 screening failures (27.5%):
Fig. 2. Patient recruitment. Of 222 patients assessed for eligibility, 161 were
randomized and 159 received the study medication. The sample size required
was calculated using nQuery Advisor 6.01. This was done for an effect size of 0.20/
0.25 = 0.8 and a power of 80%, with the result that 39 patients per treatment
group were required. ITT, intention to treat; SAE, serious adverse event; Pts,
patients; Pat, patient.
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Patients were to take 250 mg capsules of norUDCA for oral use. Groups were
divided as follows: group A, 2 x 250 mg capsules norUDCA; group B, 4 x 250 mg
capsules norUDCA; group C, 6 x 250 mg capsules norUDCA; group D, 0 (placebo).
All patients were to take 6 capsules altogether (verum + placebo) in the morning
to guarantee the blinding. The appearance, size, and taste of the placebo capsules
for oral use were indistinguishable from the verum capsules.
Study assessments
After randomization, patients were monitored at baseline visit, interim visits at
weeks 2, 4, 6, and 8, end of treatment (EOT) at week 12, and follow-up visit at
week 16 (Fig. 1). At all visits vital signs, weight, electrocardiography and body
temperature were controlled and laboratory assessments included routine serum
biochemistry (alanine [ALT] and aspartate aminotransferases [AST], gamma-
gluatmyl transpeptidase [c-GT], alkaline phosphatase [AP], total and conjugated
bilirubin, albumin, c-reactive protein [CRP], total protein, serum creatinine, lipase
lactic dehydrogenase [LDH]), hematology (blood count and differential blood
count), and blood coagulation tests (international normalized ratio [INR], partial
thromboplastin [PTT]). Abdominal ultrasound examination was done at the
screening visit and EOT. This allowed for liver size and echogenicity, the bile duct
system, gall bladder abnormalities, portosystemic collaterals, spleen size, and any
other abnormalities to be evaluated. Patients suffering from ulcerative colitis
were asked to start a diary one week before baseline until the EOT visit, to record
the four sub-scores: number of stools, blood in or on stool, general wellbeing, and
abdominal pain/cramps. This diary was used at every visit to calculate the clinical
activity index (CAI) according to Rachmilewitz generated by the electronic Case
Report Form. Pruritus was assessed by visual analogue scale (VAS) by making a
vertical line from no itching (0) to unbearable itching (100). Fatigue was assessed
by questionnaire adapted from the PBC-40 questionnaire.24 Each item was scored
on a 5-point scale and the fatigue score was calculated as the sum of scores for
the eleven items. To assess the physician’s general overall clinical impression of
the therapeutic effect and changes in the patient’s condition the physician’s glo-
bal assessment (PGA) scale was used.25 The short health scale (SHS) is a simplified
four-item questionnaire and was used for testing the patients’ quality of life.26
Compliance was recorded by counting the returned daily boxes for study medica-
tions. Adverse events (AEs) representing any unfavorable and unintended sign
and symptom including abnormal laboratory findings were recorded at each con-
trol visit. Treatment emergent AEs were defined as any event from the start of
medication and occurring within the period of treatment. SAEs included death,
any life-threatening event, requirement for in-patient hospitalization or prolon-
gation of existing hospitalization, events with persistent or significant disabil-
ity/incapacity, and congenital anomaly/birth defects.
Study endpoints
The primary efficacy variable in this clinical trial was the relative change (%) in
ALP between the baseline visit and the EOT visit (LOCF), as serum ALP is a relevant
surrogate marker for prognosis in PSC patients.27–29 This was calculated for each
patient as follows:
100 ðALP½LOCF  ALP½baselineÞ=ALP½baseline
A value of 25% calculated for a patient means a reduction by 25%, i.e. the ALP
value at EOT was three-quarters the value that was measured at the baseline visit.
Secondary efficacy endpoints included at least a 50% reduction in ALP between
baseline and EOT; normalization (\ULN) or partial normalization (\1.5 ULN)
of ALP, absolute and relative changes of ALP, c-GT, AST, ALT, and serum bilirubin
levels (total bilirubin and conjugated bilirubin) at each study visit (screening to
follow-up), absolute and relative changes of pruritus course measured by VAS,
fatigue course, and success and therapeutic benefit according to PGA.
Statistical methods
The primary efficacy variable was subject to a confirmatory statistical analysis
(p = 0.025, one-sided) in the context of a two-stage group-sequential adaptive
study design. The sample size has been chosen to ensure adequate power to
detect absolute differences in the mean relative change (%) in serum AP of about
20%. Differences of this magnitude were regarded to be clinically meaningful in
this proof of concept study. The sample size required was calculated using nQuery
Advisor 6.01. This was done for an effect size of 0.20/0.25 = 0.8 and a power of
80%, with the result that 39 patients per treatment group were required. This cal-
culation did not yet take the group-sequential adaptive study design into account.
The study was conducted according to a 2-stage group-sequential test design
with possible sample size adaptation at the interim analysis. To preserve theJournal of Hepatology 201overall (experiment-wise) one-sided type I error rate of a = 0.025 in the analysis
of the primary endpoint, boundaries calculated according to O’Brien and Fleming
were applied with a critical value at the final analysis of 2.015. The inverse nor-
mal method of combining p values was used with prospectively planned informa-
tion rates of 0.75 and 1.030 at the interim analysis and at the final analysis,
respectively. This means that a sample size of 40 patients per treatment group
was adequate (40/39 = 1.0256). The planned sample size was therefore 160
patients (1:1:1:1 randomization, i.e. about 40 patients per treatment group) in
the full analysis set (FAS) if the study was completed without modification fol-
lowing the interim analysis, which was planned after and performed based on
120 FAS patients (about 30 per group). After the interim analysis, no sample size
adaptation was required. The primary efficacy endpoint in this clinical trial was
the mean relative change (%) in serum ALP levels between the baseline visit
and the EOT visit. The absolute change from baseline to a subsequent visit and
to the EOT visit was calculated as the value at the visit minus the baseline value.
Comparisons between treatment groups were performed in two steps: The first
analysis step compared each norUDCA treatment group against placebo, the sec-
ond analysis step was used for pairwise comparisons among the three norUDCA
treatment groups. Only if all three hypotheses of the first step had been rejected,
the second step was to be performed in a confirmatory sense. In order to adjust
for multiplicity within each analysis step, a closed testing procedure using Simes
intersection tests31 was applied for each step. The inverse normal procedure was
applied to Simes adjusted p values. Corresponding p values were combined, i.e.
the p values for the global hypothesis based on patients included in the interim
analysis was combined with the p value based on the remaining patients, the
pairwise intersection p values were combined with their counterparts, as well
as the p values for the elementary hypotheses. The global hypothesis (intersection
of the 3 elementary hypotheses) could be rejected if the global test statistic (FAS)
resulting from the inverse normal method exceeded the critical value. In this case,
it was to be determined which of the elementary hypotheses could be rejected by
the closed testing procedure. One-sided p values for the analysis of the primary
endpoint were calculated using Wilcoxon rank sum tests. Calculations were per-
formed using SAS

(version 9.3, SAS Institute, USA) and using ADDPLAN
(licensed by ADDPLAN, Inc., an ICON Clinical Research, LLC company). Descriptive
statistical methods were used to analyze all variables. Continuous variables are
summarized using the number of observations, arithmetic mean, and standard
deviation. Categorical data are described using absolute and relative frequencies.
There was no considerable number of centers contributing at least three patients
per treatment group. Therefore, a possible center effect was not explored. A pos-
sible effect of geographical cluster was explored by presenting descriptive sum-
mary statistics for the primary efficacy endpoint stratified by geographical
cluster. The following geographical clusters were used: Austria, Germany, Hun-
gary, United Kingdom, Scandinavia (Denmark, Finland, Norway, Sweden), Benelux
(Belgium, The Netherlands), and other countries (Lithuania, Spain).
For further details regarding the materials used, please refer to the CTAT
table.
ClinicalTrials.gov number: NCT01755507.7 vol. 67 j 549–558 551
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Results
In total, 231 screenings were performed in 222 patients. Sixty-
one out of 222 screened patients were not eligible for randomiza-
tion. The main reason for screening failure was violation of inclu-
sion or exclusion criteria in 51 patients. The study flow chart and
additional reasons for screening failure are given in Fig. 2. Data of
screening failures and data of two patients who did not take the
study medication (one was withdrawn because of lack of cooper-
ation, the other because of violation of an exclusion criterion after
randomization) were not included in the statistical analysis. Con-
sequently, 159 received the study medication comprising the
intention to treat (ITT) analysis population. Out of the
159 patients who were treated with study medication,
21 patients discontinued the treatment phase prematurely (nor-
UDCA 500 mg: 10, 25.6%; norUDCA 1,000 mg: 4, 9.8%; norUD-
CA 1,500 mg: 3, 7.7%, placebo: 4, 10.0%). The most frequent
primary reasons were violation of inclusion or exclusion criteria
(coming to light after randomization) or intake of prohibited con-
comitant medication. The number of patients terminating the
treatment phase because of lack of efficacy was: norUD-
CA 500 mg: 1 patient, norUDCA 1,000 mg: 0 patient, norUDCA
1,500 mg: 1 patient, and two in the placebo group.Patient characteristics
The main baseline characteristics of the 159 patients treated are
shown in Table 1. Overall and for each treatment group, the
majority of patients were male (109/159; 68.6%), reflecting the
natural gender distribution in PSC patients. There was no signif-
icant difference between study groups with regard to age, weight,
height, BMI, and ALP serum levels at baseline indicating that the
four treatment groups were well balanced at enrollment. A range
from 6 to 8 of newly diagnosed PSC patients was comparableTable 1. Demographic and baseline characteristics of randomized and treated patie
Placebo
(N = 40)
Male, N (%) 25 (62.5%)
Female, N (%) 15 (37.5%)
Age (yr), (mean SD) 44.1 (14.89)
Weight (kg), (mean SD) 78.7 (13.63)
Height (cm), (mean SD) 176.0 (12.14)
BMI (kg/m2), (mean SD) 25.5 (3.93)
Duration of PSC (Months), (median range) 83 (2–343)
New diagnosis of PSC, N (%) 8 (20.0%)
IBD at screening
Ulcerative colitis, N (%)
Crohn‘s disease, N (%)
50%
15 (37.5%)
5 (12.5%)
Time since first IBD symptoms
(Months), (median range)
162 (36–451)
ALP at baseline (U/L), (mean SD) 456 (234.4)
UDCA naïve, N (%) 12 (30.0%)
UDCA pre-treatment, N (%) 27 (67.5%)
Responder, N (%)
Mean previous dose, mg/kg/d
18 (66.7%)
14.5
Non-responder, N (%)
Mean previous dose, mg/kg/d
9 (33.3%)
14.3
Unknown UDCA exposure, N (%) 1 (2.5%)
552 Journal of Hepatology 201between the different treatment groups, ranging from 15% and
20% (Table 1), with the highest percentage in the placebo group.
The rate of concomitant IBD was highest within the norUDCA 500
mg group (77%) and lowest within the placebo group (50%), how-
ever this difference did not reach statistical differences. There
was no correction for IBD presence with respect to allocation of
treatment groups. In the active treatment groups, the median
time since the first symptoms of IBD was about 13.5 years, and
the median duration of IBD disease was about 11.5 years
(Table 1). The median duration of PSC was 6.9 years in the pla-
cebo group and 6.9, 3.7, and 4.3 years in the 500, 1,000, and
1,500 mg norUDCA group respectively (variation not greater than
expected by chance). Serum ALP values were profoundly elevated
at baseline in all treatment groups ranging from 369 IU/L in the
norUDCA 1,000 mg group to 495 IU/L in the norUDCA 500 mg
group, indicating that all treatment groups had pronounced
cholestasis. Out of 159 study patients, 113 (71.0%) were UDCA
experienced, 58 (51.3%) of these were UDCA responders defined
by partial normalization of ALP at investigator’s discretion and
55 (48.7%) UDCA non-responders. Forty out of 159 (25.2%)
patients were UDCA naїve, the response to previous UDCA treat-
ment was unknown or not applicable for the remaining 6/159
(3.8%) randomized patients (Table 1). In the active treatment
groups, the proportion of UDCA non-responders ranged between
51.8% in norUDCA 1,500 mg group and 54.8% in the norUDCA
1,000 mg group, whereas in the placebo group only 33.3% were
UDCA non-responders, defined according to the investigators’
discretion (and therefore lacking a universal definition). The
UDCA doses were in a similar range (between 12 and 15 mg/kg/
d) in UDCA responders and non-responders (Table 1). There
was no difference between the groups with regard to current pru-
ritus or previous pruritus episodes reported by patients ranging
from 40.0% in the placebo groups to 64.1% in the norUDCA 500
mg group. Fatigue at baseline was reported from 45.0% in the pla-
cebo group up to 70.7% in the norUDCA 1,000 mg group.nts.
norUDCA
500 mg
(N = 39)
norUDCA
1,000 mg
(N = 41)
norUDCA
1,500 mg
(N = 39)
27 (69.2%) 28 (68.3%) 29 (74.4%)
12 (30.8%) 13 (31.7%) 10 (25.6%)
40.9 (12.24) 42.3 (13.08) 41.0 (13.11)
75.5 (13.51) 79.1 (15.37) 77.7 (15.65)
176.0 (9.01) 175.7 (8.06) 176.9 (11.30)
24.3 (3.87) 25.6 (4.94) 24.8 (3.78)
83 (1–345) 45 (2–242) 52 (2–311)
6 (15.4%) 8 (19.5%) 7 (17.9%)
77%
27 (69.2%)
3 (7.7%)
65%
22 (53.7%)
5 (12.2%)
64%
24 (61.5%)
1 (2.6%)
183 (10–416) 151 (4–526) 140 (11–476)
495 (282.4) 369 (200.6) 464 (241.6)
9 (23.1%) 9 (22.0%) 10 (25.6%)
28 (71.8%) 31 (75.6%) 27 (69.2%)
13 (46.4%)
13.7
14 (45.2%)
12.2
13 (48.2%)
13.3
15 (53.6%)
13.0
17 (54.8%)
14.4
14 (51.8%)
15.3
2 (5.1%) 1 (2.4%) 2 (5.1%)
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Fig. 3. Percentage change in serum levels of ALP after 12 weeks compared to
baseline values. Serum ALP levels decreased in a dose-dependent manner in
response to norUDCA treatment with the most pronounced reduction in the
1,500 mg norUDCA arm. NU, norUrsodeoxycholic acid.*Indicates p\0.01 com-
pared to placebo; #Indicates p\0.025 comparison of NU 1,500 mg vs. NU 500 mg.
A closed testing procedure using Simes intersection tests31 was applied for each
group comparison (comparison of each norUDCA treatment group against placebo
and pairwise comparisons among the three norUDCA treatment groups). The
inverse normal procedure was applied to Simes adjusted p values. One-sided p
values for the analysis of the primary endpoint were calculated using Wilcoxon
rank sum tests.
JOURNAL OF HEPATOLOGYNorUDCA significantly reduces serum ALP levels in a dose-dependent
fashion in PSC patients
The relative reduction of serum ALP values was chosen as the pri-
mary endpoint for this study, since ALP levels currently represent
the best available surrogate parameter for PSC patients and
therefore appeared most suitable for this short-term study.27–29
In each norUDCA group, the relative reduction of serum ALP
was statistically significantly superior to placebo in the analysis
of the primary endpoint showing dose-dependent reductions by
12.3%, 17.3%, and 26.0% in the 500, 1,000, and 1,500 mg/d
norUDCA groups respectively (Fig. 3). Thus, the study was posi-
tive on ITT for all norUDCA treatment groups. Statistically signif-
icant differences compared to placebo were also seen for all three
norUDCA groups in the per protocol set (data for per protocol
analysis not shown). Possible confounding effects of geographical
clusters were not detected by stratified analysis of the relative
reduction of serum ALP (data not shown). The percentage of trea-
ted patients reaching prognostically meaningful reductions of
ALP defined as serum levels 61.5-fold the ULN27,28 was: 12.5%
(5/40) in the placebo group, 12.8% (5/39) in the norUDCA 5000
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Fig. 4. Absolute changes in serum ALP, cGT, ALT, and AST levels throughout the stud
norUrsodeoxycholic acid. Placebo group, gray circles; 500 mg NU group, black circles; 1
statistical methods were used to analyze all variables. Continuous variables are summar
Journal of Hepatology 201mg group, 41.5% (17/41) in the 1,000 mg group (the group start-
ing with the lowest ALP levels), and 30.8% (12/39) in the 1,500 mg
group. ALP levels within ULN were found in 2/40 (5.0%) of the
placebo group, 1/39 (2.6%) of the norUDCA 500 mg group, 5/41
(12.2%) in the 1,000 mg group, and 4/39 (10.3%) of the
1,500 mg group. Moreover, all three norUDCA doses induced a
rapid decrease in serum ALP levels within 4 weeks, which was
again most pronounced in the highest norUDCA treatment group
(Fig. 4A). A post-hoc analysis with respect to the daily norUDCA
dose/kg body weight confirmed the main result of this study, as
well as a dose selection for the phase III program (data not
shown). Serum ALP levels remained relatively stable throughout
the treatment period in the norUDCA treatment arms, but
returned nearly to baseline levels at the end of the follow-up per-
iod, indicating a pronounced rebound of serum ALP levels follow-
ing discontinuation of norUDCA treatment. In contrast, in the
placebo group ALP levels increased 1.2% during the study period
until EOT (Fig. 3). Interestingly, ALP serum levels decreased in the
placebo group from EOT to the follow-up visit. This could at least
in part be related to more frequent reintroduction of UDCA treat-
ment in the placebo arm (9/40 = 22.5% patients; vs. 4/39 = 10.3%
norUDCA 500 mg; 2/41 = 4.9% norUDCA 1,000 mg; 5/39 = 12.8%
norUDCA 1,500 mg) following the active treatment period upon
physician’s discretion. It may also be of interest to note that 8
out of these 9 patients were classified as UDCA responders before
study entry and that the proportion of patients receiving UDCA
after placebo in the follow-up period was about double the num-
ber in the active treatment groups (Table S1). Serum bilirubin
levels did not significantly differ between treatment groups at
the different time points (Table S2).NorUDCA significantly reduces c-GT, ALT, and AST serum levels in
PSC patients
NorUDCA significantly reduced serum c-GT levels in a dose-
dependent fashion, and was most pronounced with a mean
reduction of 33.9% in the norUDCA 1,500 mg group (for absolute
values see Fig. 4B). Notably, the dose-dependency of the bio-
chemical norUDCA effects in the reduction of serum enzyme
levels was most apparent for serum c-GT compared to the other
serum parameters (Fig. 4). In parallel to the reduction of the cho-
lestatic liver enzymes, the median reduction of serum AST levels
was 20.5% and 33.1% in ALT levels at EOT (for absolute values see
Fig. 4C and D, respectively). As observed for ALP, following a sig-
nificant reduction under norUDCA treatment, a pronounced20
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Table 2. Relative changes (%) in ALP serum levels from baseline to EOT according to UDCA pretreatment as well as UDCA treatment response and other clinical
parameters.
Placebo
(N = 40)
norUDCA
500 mg
(N = 39)
norUDCA
1,000 mg
(N = 41)
norUDCA
1,500 mg
(N = 39)
Male, mean % (N) +4.7% (25) 14.1% (27) 13.9% (28) 27.8% (29)
Female, mean % (N) 4.6% (15) 8.3% (12) 24.7% (13) 20.5% (10)
UDCA responder, mean % (N) 6.2% (18) 9.9% (13) 16.4% (14) 19.5% (13)
UDCA non-responder, mean % (N) 3.5% (9) 10.1 (15) 14.9% (17) 27.3% (14)
UDCA naïve, mean % (N) +12.3% (12) 14.9% (9) 24.8% (9) 32.0% (10)
ALP[3  ULN, mean % (N) 0.9% (25) 14.4% (23) 19.7% (17) 26.2% (22)
ALP 6 3  ULN, mean % (N) 4.8% (15) 9.2% (16) 15.6% (24) 25.7% (17)
PSC with IBD, mean % (N)* 5.8% (20) 10.4% (29) 14.5% (27) 24.0% (27)
PSC without IBD, mean % (N)* 4.8% (18) 21.8% (8) 22.8% (14) 29.9% (11)
PSC duration 65 yr, mean % (N)** 8.3% (15) 10.5% (17) 20.3% (22) 28.2% (20)
PSC duration[5 yr, mean % (N)** 3.0% (24) 13.7% (22) 13.4% (18) 23.7% (19)
* In N = 5 no classification to IBD or non-IBD was possible.
** In N = 2 data from the first PSC diagnosis was not documented.
Research Articlerebound of c-GT, AST, and ALT serum levels was evident from
EOT to the follow-up visit.
NorUDCA response is not predicted by previous UDCA treatment,
previous UDCA response, presence of IBD, or duration of PSC
Importantly, a dose-dependent reduction of ALP was observed in
both sexes and independent of previous UDCA-pretreatment and
response (Table 2). Similarly, presence of IBD, duration of PSC and
baseline ALP levels had no impact on the dose-dependent
response to norUDCA (Table 2). Notably, the percentage of
patients without therapeutic response to norUDCA (defined as
an ALP at EOT above screening values when most patients were
still on UDCA) declined sharply with increasing norUDCA doses,
again independently of previous UDCA pretreatment and
response (Fig. S1).Patient related outcomes
Body weight, body temperature, and vital signs did not show any
relevant changes from baseline to EOT in all four treatment
groups. It is interesting to note, that 7 (17.9%) patients showed
enlarged spleen at baseline in the norUDCA 500 mg group, 3
(7.3%) in the 1,000 mg group, and 3 in the 1,500 mg group. At
EOT this number was reduced to 4 (10.3%), 0, and 0 patients in
each verum-treated group respectively, while the number of
patients with enlarged spleen was 2 (5%) in the placebo group
at baseline and increased to 3 (7.5%) at EOT. The mean values
of CAI sum were low in all treatment groups at baseline and
EOT (1.3/1.7 norUDCA 500 mg group, 0.9/1.0 1,000 mg group,
2.0/1.3 1,500 mg group, and 2.1/1.5 in the placebo group). The
sub-scores with the highest mean values at baseline were; score
for number of stools, score for general wellbeing, score for bloody
stools, score for abdominal pain/cramps and laboratory findings.
Sub-scores showed some variability but no trend among treat-
ment groups. In addition, there was no statistical significant dif-
ference in SHS scores between treatment groups but indicated a
slight improvement from baseline to EOT for the norUDCA
1,500 mg group for each individual dimension. Using the sum
of eleven questions for the calculation of the fatigue score there
was no significant difference from baseline (placebo: 23.0, nor-
UDCA 500 mg: 21.0, 1,000 mg: 19.7, 1,500 mg: 23.3) to EOT (pla-
cebo 21.3, norUDCA 500 mg: 20.7, 1,000 mg: 19.8; 1,500 mg:554 Journal of Hepatology 20120.2) and between treatment groups. However, a slight improve-
ment of symptoms according to PGA of efficacy could be achieved
at EOT for 43.6% of patients in the 1,500 mg norUDCA group,
29.3% in the 1,000 mg, 23.1% in the 500 mg, and 30% in the pla-
cebo group. These differences did not reach statistical
significance.NorUDCA showed a favorable safety profile
Tolerability of the study medication was described as very good
in the vast majority of patients and investigators. A poor tolera-
bility was described only by two patients (4.9%) in the norUDCA
1,000 mg group and by one patient (2.5%) in the placebo group.
Tolerability was described as equally good in all treatment arms.
No patient died during the course of this study. The percentage of
treatment emergent AEs was 80%, 59%, 73%, and 67% in the pla-
cebo group, for the norUDCA 500 mg, the norUDCA 1,000 mg
group, and norUDCA 1,500 mg groups respectively. In total eight
treatment emergent SAEs were noted in 8 patients, 3 in the nor-
UDCA 500 mg group, 1 in the norUDCA 1000 mg, 1 in the 1500
norUDCA group, 3 in the placebo group. The number of treatment
emergent SAEs was therefore similar between treatment groups.
Only one SAE in the placebo group was described by an investi-
gator as possibly being related to investigational medicinal pro-
duct (IMP) (ocular icterus/lack of clinical efficacy). An
additional five SAEs, not related to treatment, were also catego-
rized as ‘‘disease progression/lack of clinical efficacy”. The
remaining two SAEs were a removal of meniscus and a diagnosis
of colon cancer 4 days after start of treatment. Treatment emer-
gent AEs reported in more than 10 patients were abdominal pain
(11), fatigue (13), nasopharyngitis (30), headache (13), and pruri-
tus (17). There were no differences in the incidence of AEs
between treatment groups related to dose-dependent effects,
and none compared to placebo. In addition, the percentage of
adverse drug reactions was comparable in all groups with 28%,
23%, 32%, and 28% in the placebo group, for the norUDCA
500 mg, the norUDCA 1,000 mg, and norUDCA 1,500 mg groups
respectively. The most common AEs with the most prominent
being nasopharyngitis in all treatment groups are listed in Table 3.
Notably, pruritus occurred similarly across treatment arms and
generally at low frequencies: 7 events in the 500 mg/d group, 7
in the 1,000 mg/d group, 12 in the 1,500 mg/d group, and 10 in
the placebo group. Importantly pruritus was mild and no patient7 vol. 67 j 549–558
Table 3. Most common adverse events.
Placebo
(N = 40)
norUDCA
500 mg
(N = 39)
norUDCA
1,000 mg
(N = 41)
norUDCA
1,500 mg
(N = 39)
Abdominal pain 5 (12.5%) 1 (2.6%) 4 (9.8%) 1 (2.6%)
Diarrhea 4 (10.0%) 0 (0.0%) 1 (2.4%) 3 (7.7%)
Fatigue 4 (10.0%) 2 (5.1%) 2 (4.9%) 5 (12.8%)
Nasopharyngitis 7 (17.5%) 6 (15.4%) 9 (22.0%) 8 (20.5%)
Arthralgia 4 (10.0%) 1 (2.6%) 1 (2.4%) 0 (0.0%)
Back pain 4 (10.0%) 1 (2.6%) 0 (0.0%) 3 (7.7%)
Headache 3 (7.5%) 2 (5.1%) 1 (2.4%) 7 (17.9%)
Pruritus 4 (10.0%) 3 (7.7%) 4 (9.8%) 6 (15.4%)
Number of patients (%) with treatment emergent adverse events.
JOURNAL OF HEPATOLOGYdiscontinued treatment. There were no significant differences of
scores for pruritus between baseline visit (placebo 15.4, 500 mg
9.9, 1,000 mg 14.8, 1,500 mg 16.5; scale 0–100 mm) and EOT
(placebo 15.3, 500 mg 10.8, 1,000 mg 20.9, 1,500 mg 15.2) and
between all treatment groups. There was no effect on IBD
activity. Taken together the safety profile of norUDCA seems to
be favorable and no warning signs emerged from the data of this
study.Discussion
For decades there has been no significant progress in the medical
therapy of PSC. This double-blind, randomized, placebo-
controlled, dose finding study is a proof of concept study and
the first human study with norUDCA to assess its efficacy, safety
and tolerability in PSC patients. The main findings of the study
are: (i) norUDCA resulted in a significant reduction of ALP values
in PSC patients within 12 weeks of treatment compared to pla-
cebo, (ii) the positive effects occurred in a dose-dependent man-
ner, and (iii) the safety profile of norUDCA was comparable to
placebo in our study.
All three norUDCA doses tested in this study resulted in a sig-
nificant reduction in ALP, which was most pronounced in the
1,500 mg arm and consequently all norUDCA treatment arms
reached the primary efficacy endpoint at ITT analysis as defined
for this study. In addition, the decline in ALP levels was paralleled
by significant reductions in ALT, AST, and c-GT levels. In particu-
lar, the time course of c-GT levels uncovered the most
pronounced relationship between norUDCA doses and its
biochemical effect. In addition to serving as a biochemical param-
eter of cholestasis in PSC patients, serum c-GT levels may also
reflect inflammation-triggered hepatic oxidative stress,32–34
which may be significantly reduced upon norUDCA treatment as
observed previously in preclinical models.14–17 Since spleen size
may also reflect PSC activity35 it is worth noting that 13 verum-
treated patients showed increased spleen size at baseline but only
4 patients at EOT. Potential anti-inflammatory effects of norUDCA
need detailed futuremechanistic studies. Interestingly, patients in
the placebo arm showed a decrease in all serumparameters tested
in the follow-up period of the study comparable to the effect of
norUDCA in the verum group. This maybe primarily related to
the more frequent reintroduction of UDCA treatment in this study
group of patients who continued to show profoundly elevated
cholestasis parameters throughout the treatment period, after
discontinuation of UDCA in the pre-study washout phase. It is also
important to note that the most pronounced relative decrease in
serum ALP levels was observed in the 1,500 mg norUDCA groupJournal of Hepatology 201with a 26% reduction indicating a dose-dependent effect of nor-
UDCA. This observation, as well as the fact the 1,500 mg norUDCA
dose was also well tolerated, is also relevant for the dose selection
of future phase III clinical trial in PSC patients. Importantly 12.8%
of patients achieved a reduction of serum ALP levels 61.5 the
ULN in the norUDCA 500 mg group, 41.5% in the 1,000 mg nor-
UDCA group, 30.8% in the 1,500 mg norUDCA group, and 12.5%
in the placebo group, which was previously shown to be of poten-
tial prognostic importance in PSC patients.28,36,37
Although a direct comparison of the current study with previ-
ous UDCA trials in PSC is not possible due to substantial differ-
ences in study design, UDCA has also demonstrated pronounced
ALP reduction in the range observed for norUDCA herein or even
higher.6–8 Along these lines, it is also important to note that in
the post-hoc analyses of the very high dose UDCA trials as
reported by Stanich et al.27 and of the Scandinavian UDCA trial
by Lindström et al.,38 patients with normalization of ALP had a
better prognosis, although this was not necessarily related to
UDCA use. This may underscore the prognostic relevance of ALP
normalization in PSC patients, but also points towards a potential
dissociation from active drug (UDCA) treatment. Importantly,
based on our preclinical findings norUDCA can be expected to
have profoundly different/additional mechanisms than UDCA,
which may not be fully reflected by biochemical improvement
in short-term phase II studies. For our current study, it is essential
to note that the observed response to norUDCA treatment was
independent of whether patients were UDCA-naïve or -
experienced and whether the physicians categorized them as
UDCA non-responder or responders. There may however still be
PSC patients who may benefit from UDCA treatment, potentially
those with a significant reduction in ALP serum levels. Interest-
ingly, the norUDCA-induced fall in serum ALP levels was most
pronounced within the first two weeks of treatment. Conse-
quently, it appears plausible that norUDCA may reduce the vis-
cosity of bile immediately after starting the treatment, since it
represents a potent pharmacological inducer of biliary bicarbon-
ate secretion and therefore protects the liver.39
The safety profile of norUDCA as observed in our study was
very encouraging. Most importantly there was no statistical dif-
ference with relation to treatment emergent AEs between nor-
UDCA and placebo arms. The most frequently reported
complaints were related to nasopharyngitis, which was also com-
parable between all treatment arms. The number of reported
SAEs was generally low and equally in all treatment arms. Conse-
quently, the reported AEs in this study do not raise alarm for nor-
UDCA treatment in PSC patients. This is particularly important for
pruritus, which was not more frequently observed in the nor-
UDCA arms, as pruritus may represent a serious problem associ-
ated with bile acid treatment in cholestatic patients.40–42 We did
not observe any significant differences concerning fatigue score,
CAI, and PGA between baseline and EOT in all treatment arms.
However, it may be overambitious to expect significant differ-
ences within 12 weeks of norUDCA treatment; notably we also
observed no worsening in these scores, which indicates at least
that norUDCA was well tolerated in all active treatment arms.
Importantly, this norUDCA study, the first conducted in humans,
excluded patients with main bile duct strictures or recent need
for endoscopic therapy, as we had potential concerns regarding
the potent choleretic actions of norUDCA observed preclini-
cally.23,14,15 Predicting the relative risk for potential aggravation
of portal hypertension or the development of bile infarcts in7 vol. 67 j 549–558 555
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norUDCA-treated PSC patients with more advanced disease or
main bile duct strictures will be very challenging. This may
become even more complex when combination therapy of nor-
UDCA with UDCA is considered in future studies, since the com-
pounds may have additive beneficial effects.23 Therefore closely
spaced, clinical, and biochemical controls will be necessary for
the best safety of our patients in a future phase III clinical trial.
This norUDCA phase II dose finding study in PSC has several
limitations including the lack of C4 bile acids and FGF19 serum
levels. The primary efficacy variable of this phase II clinical trial
was defined as the relative change (%) in serum ALP between
the baseline visit and the EOT, since ALP, transient elastography,
and histology are currently seen as the most promising candidate
surrogate endpoints for clinical trials in PSC patients.29,36,43,44
However, pronounced changes in liver stiffness or liver histology
may be rather ambitious to expect within a short treatment per-
iod of 12 weeks in PSC patients and therefore have not been cho-
sen as primary endpoints for this study. Moreover, the observed
significant reduction in ALP values in all norUDCA treatment arms
in our study should not be overestimated at this stage. A random-
ized controlled trial testing high doses of UDCA (17 to 23 mg/kg/-
day) showed a favorable biochemical trend but lacked significant
effects on hard clinical endpoints such as transplant-free survival
and was in addition probably underpowered.10 Testing even
higher doses (28–30 mg/kg/day) in PSC patients again revealed
an improvement in serum liver tests including ALP but were
associated with adverse clinical outcomes.11 In the current study,
PSC patients with more advanced disease with Child-Pugh class B
and C and those with serum bilirubin levels higher than 3 mg/dl
have been excluded due to potential safety reasons. Conse-
quently, it is currently unclear whether norUDCA will be safe to
use in these patients.
In summary, the herein presented findings justify a phase III
clinical trial for norUDCA treatment in PSC patients. The design
of such a trial poses several key questions: (i) a future study
should consider combined endpoints with serum ALP levels, tran-
sient elastography, proper assessment of spleen size, and liver
histology. Hard clinical endpoints such as need for liver trans-
plantation or death will be unrealistic study endpoints for such
a rare disease with a highly variable clinical course. (ii) The differ-
ent therapeutic mechanisms and pharmacodynamics of norUDCA
and its mother compound UDCA may provide a potential ratio-
nale for combining norUDCA and UDCA in the treatment of PSC,
which has to be demonstrated in a combination therapy arm.
(iii) Based on our current data the daily norUDCA dose of
1,500 mg was proven to be efficacious and safe, and therefore
should be further tested in a phase III clinical trial.Financial support
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